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EXAMINING THE RELATIONSHIP BETWEEN MITOCHONDRIAL 
DYSFUNCTION AND PARKINSON’S DISEASE PATHOLOGY: DISCOVERING 
POTENTIAL RISK FACTORS AND TREATMENTS FOR PARKINSONISM 
 
HARRISON BONILLA 
 
ABSTRACT 
The most prevalent histological risk factor for Parkinson’s disease is the 
development of alpha-synuclein clumps, known as Lewy Bodies, in the substantia nigra 
portion of the midbrain. However, the etiology of the disease remains unknown. Neurons 
are heavily dependent on aerobic respiration for ATP due to their high energy demands. 
In neurons, mitochondria are transported throughout axons and dendrites for facilitating 
subcellular functions, and are critically important for membrane excitability and 
neurotransmission. Past evidence indicates that mitochondrial dysfunction plays a 
significant role in the progression of degenerative pathologies in the brain. In this review, 
genetic factors and biochemical mechanisms representative of healthy mitochondrial 
structure and function are examined to determine the role of mitochondrial dysfunction in 
the onset and progression of Parkinson’s disease. Treatments and therapies targeting 
mitochondrial dysfunction for the purposes of improving Parkinson’s disease pathologies 
are also explored. 
Published data examined in this review has shown that mitochondrial dysfunction 
plays a significant role in the development and progression of Parkinson’s disease. 
Through interactions with alpha-synuclein protein aggregates and through facilitation of 
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general dopaminergic neurodegeneration, mitochondrial dysfunction provides a pathway 
for the progression of Parkinsonian pathologies. In addition, genes involved with 
mitochondrial biogenesis, as well as genes involved in the onset of Parkinson’s disease 
show overlap and interactions indicative of an association between defective 
mitochondria and parkinsonism. With a focus on improving mitochondrial function and 
reducing Parkinson’s disease pathology, a number of potential drug treatments and 
therapies have proven to be of interest. 
 While there is currently no cure for Parkinson’s disease, evidence consolidated in 
this review supports the need for investigation into Parkinson’s disease treatments that 
target mitochondrial dysfunction and oxidative stress. Subsequent research studies and 
treatments should focus on genes that play a regulatory role in mitochondrial biogenesis, 
with the goal of determining more transcriptional pathways that overlap between 
mitochondrial dysfunction and parkinsonism. Drug compound screens for improving 
mitochondrial biogenesis and reducing alpha-synuclein aggregation should be explored 
as well.  
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INTRODUCTION 
 
Parkinson’s Disease Background 
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
in the world, and affects more than 10 million people worldwide, with more than one 
million people affected in the United States (Weintraub & Comella, 2008). PD is 
associated with a loss of dopaminergic neurons in the pars compacta portion of the 
substantia nigra region of the midbrain (Kalia & Lang, 2015). The symptoms of PD are 
physically and psychologically debilitating for both the affected individual and their 
loved ones, with progressively worsening symptoms that include muscle tremors, 
difficulty with movement, and cognitive and speech impairments (Sigurlaug, 2016). One 
of the hallmarks of PD is the presence of α-synuclein (ASN) protein clumps in the 
brainstem, known as Lewy bodies (Weintraub & Comella, 2008). ASN is normally a 
monomeric protein that is encoded by the SNCA gene (Diao et al., 2013). It consists of 
three distinct domains: an amphipathic N-terminal alpha-helical region, a central 
hydrophobic region which includes the non-amyloid-beta component region involved in 
protein aggregation, and a highly acidic, proline-rich region (Clayton & George, 1998). A 
graphic of ASN has been provided in Figure 1, with the different domains illustrated, and 
the PD-associated mutation sites shown. It is one of the most common proteins in the 
brain, comprising around 1% of the protein in each neuron. ASN is associated with pre-
synaptic vesicles, and has recently been shown to function as a molecular chaperone in 
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the formation of SNARE complexes, binding to phospholipids on the plasma membrane 
via its N-terminus domain (Diao et al., 2013).  
 
 
Figure 1. Alpha-synuclein structure. Adapted from (Ottolini et al., 2016) 
 
 Accumulation of ASN protein clumps is speculated to play a prominent role in 
the pathogenesis of both familial and sporadic cases of PD (Weintraub & Comella, 2008). 
ASN appears to interact with many proteins and membrane components such as 
phospholipids, and appears to influence numerous signaling pathways. There is a strong 
correlation between the progression and severity of PD and the Lewy body pathology 
(Weintraub & Comella, 2008). Increased risk of parkinsonism through ASN aggregation 
can be modulated by environmental and genetic factors such as oxidative stress, 
dopamine levels, neuronal proteins such as parkin, and most directly, mutations in the 
ASN gene SNCA (Kalia & Kalia, 2015). 
 Despite being one of the most common neurodegenerative diseases, there is 
currently no cure for Parkinson’s disease. There are only treatments for mediating 
symptoms, which include drugs for increasing dopamine levels, such as levodopa, drugs 
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for preventing dopamine breakdown such as the monoamine oxidase B inhibitor 
selegiline and the catechol-O-methyltransferase inhibitor entacapone, dopamine agonists 
such as apomorphine (Chaudhuri et al., 2006), surgical interventions such as deep brain 
stimulation (Benabid et al., 2009), and complementary therapies such as improved diet 
and exercise. Estimates suggest that about 60,000 Americans are diagnosed with PD each 
year, with the average age of onset being 60 years old (Weintraub & Comella, 2008). 
With a growing geriatric population, the prevalence of PD and related neurodegenerative 
disorders is only increasing. Furthermore, the disease is economically costly, with direct 
and indirect costs including treatment, social security payments, and lost income 
estimated to be around 25 billion dollars in the United States alone. Medications for 
treating Parkinson’s Disease cost an average of $2500 per year per person with PD in the 
United States, and therapeutic surgeries can cost up to $100,000 per individual patient 
(Weintraub & Comella, 2008). With the prevalence of Parkinson’s Disease only 
increasing, a need for a viable and effective treatment is crucial.  
 
Mitochondrial Biogenesis and Parkinson’s Disease 
Most human cells are dependent on mitochondria in order to properly function. 
Neurons are especially dependent on mitochondria, due to their high rates of metabolic 
activity and the bioenergetic demands placed on neurons in transmitting information at 
pre- and post-synaptic sites (Hwang, 2013). Pre-synaptically, this neuronal 
communication requires energy and generates large changes in calcium concentrations 
(Vos, Lauwers, & Verstreken, 2010). Mitochondria supply the necessary energy for 
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neuronal activity, and help buffer calcium, and so are crucial at pre-synapses. 
Mitochondria are also paramount in their role in maintaining neuronal homeostasis and 
typical neuronal function. Mitochondrial electron transport generates the ATP that is 
essential for the excitability and survival of neurons, and the protein phosphorylation 
reactions that mediate synaptic signaling and related long-term changes in neuronal 
structure and function. (Mattson, Gleichmann, & Cheng, 2008). Mitochondria are present 
at a higher concentration in neurons due to the energy demands required for maintaining 
neuronal function. Therefore, because of the abundance of mitochondria in neurons as 
compared to other cells in the body, neurons are particularly susceptible to mitochondrial 
dysfunction. There is also evidence for mitochondrial dysfunction having a central role in 
age-related neurodegenerative diseases, as mitochondria help regulate cell death, which is 
a fundamental characteristic of neurodegenerative disease (Hwang, 2013). Damaged 
mitochondrial function is likely to increase oxidative stress, which, along with mutations 
in mitochondrial DNA, also contribute to aging, the risk factor common in all 
neurodegenerative diseases (Payne & Chinnery, 2015). Damage to mitochondria or 
reduced mitochondrial activity thus plays a role in the advancement of neurodegenerative 
disease, with many pathways potentially involved with PD pathogenesis, as shown in 
Figure 2.  
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Figure 2. Representative pathways of mitochondrial dysfunction involved in Parkinson’s disease 
pathophysiology. Mitochondrial dysfunction associated with PD pathogenesis can result from impairment 
of mitochondrial biogenesis, increased reactive oxygen species production, defective mitophagy, 
compromised trafficking, electron transport chain dysfunction, variations to mitochondrial dynamics, 
calcium imbalance or combinations thereof. The potential complex interplay of the various functions leads 
to a vicious cycle of progressive cellular dysfunction that ultimately results in neurodegeneration that 
underlies PD pathogenesis and progression. Adapted from (Park et al., 2018). 
 
 
In particular, reduced activity of complex I of the electron transport chain has 
been implicated in the onset of mitochondrial permeability transition pore-induced 
parkinsonism, as well as in inducing idiopathic PD (Perier & Vila, 2012).  The 
association between complex I and the induction of parkinsonism was discovered due to 
the accidental exposure of drug users to the compound 1-methyl-4-phenyl-1,2,3,4-
tetrahydropyridine (MPTP), which serves as an inhibitor of complex I (Perier & Vila, 
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2012). The MPTP exposure led to pathologies similar to those found in Parkinson’s 
disease patients. MPTP was also shown to kill dopaminergic neurons in the substantia 
nigra pars compacta when injected into nonhuman primates and mice (Perier & Vila, 
2012). Research studies have reported reduced complex I activity in the brain of patients 
with idiopathic Parkinson’s disease (Perier & Vila, 2012). Like MPTP, the complex I 
inhibitor rotenone has been shown to produce nigrostriatal dopaminergic degeneration 
(Perier & Vila, 2012). In fact, the inhibition of complex I of the mitochondria by systemic 
infusion of rotenone in rats retrograde leads to degeneration of the substantia nigra, 
creating a replicate model for Parkinson’s disease (Xiong et al., 2012).  
Recent research has also shown that several Parkinson’s disease-associated genes 
are involved in pathways that regulate mitochondrial function (Perier & Vila, 2012). 
Therefore, there is a need for examining the overlap between PD-associated genes and 
mitochondrial genes. 
 
Genetic Association between Mitochondrial Dysfunction and PD 
Approximately 90% of neuropathological Parkinson’s disease cases are sporadic, 
with no clear etiology, and a combination of environmental factors or toxins, genetic 
susceptibility, and aging are speculated to account for many sporadic cases (Weintraub & 
Comella, 2008). 10% of cases have a genetic origin, with at least 11 different linkages 
with 6 gene mutations having been identified. 
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In the current PD nomenclature, there are 18 specific chromosomal regions, 
termed PARK, that have been identified as having an association with both sporadic and 
familial forms of PD, the most commonly affected of which are shown in Table 1.  
 
 
Symbol Gene Locus Disorder Inheritance Gene 
PARK1 4q21-22 EOPD AD SNCA 
PARK2 6q25.2-q27 EOPD AR Parkin 
PARK4 4q21-q23 EOPD AD SNCA 
PARK6 1p35-p36 EOPD AR PINK1 
PARK8 12q12 Classical PD AD LRRK2 
 
Table 1. PARK-Designated PD-related Loci. AD = Autosomal Dominant, AR = Autosomal Recessive. 
EOPD = Early-Onset Parkinson’s Disease Adapted from (Klein & Westenberger, 2012). 
 
Among the genes identified as monogenic causes of familial PD, there are many that are 
associated directly with mitochondrial dysfunction. Major ones among these are the 
genes for ASN, LRRK2, Parkin, and PINK1 (Park, Davis, & Sue, 2018).  
The autosomal dominant SNCA gene mutation was the first identified in the 
familial PD gene. It has an association with mitochondrial dysfunction due to its role in 
over-producing ASN. ASN can localize into mitochondrial membranes, and disrupt 
mitochondrial energy production (Paillusson et al., 2017). ASN can influence 
mitochondrial biogenesis via regulation of peroxisome proliferator-activated receptor 
gamma coactivator 1-α (PGC-1α) (Ryan et al., 2013).  PGC-1α is one of the main 
transcriptional regulators of mitochondrial biogenesis and function (Li et al., 2017), and 
research has shown that PGC-1α nigral neurons in mice are prone to degeneration 
following overexpression of ASN, with mitochondrial morphology, oxidative stress 
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detoxification, and basal respiration restored with PGC-1α overexpression (Ciron et al., 
2015).  
 Autosomal dominant mutations in the leucine rich repeat kinase 2 (LRRK2) gene 
have been identified as the most common cause of familial PD (Lill, 2016). LRRK2 gene 
mutants exhibit increased kinase activity. Models of over-expressed mutant LRRK2 have 
shown increased vulnerability to mitochondrial toxins, defective mitochondrial function, 
and an increase in free radical production (Ryan et al., 2015). The most common 
autosomal recessive mutations in PD genes that are associated with mitochondrial 
dysfunction include the parkin and PINK1 gene mutations (Park, Davis, & Sue, 2018). 
Sporadic causes of Parkinson’s Disease are multifactorial, with undetermined 
genetic and environmental factors playing a role. However, genome wide association 
studies have identified polymorphisms in familial PD genes associated with 
mitochondrial dysfunction that are risk factors for developing sporadic PD, which include 
the parkin, PINK1, SNCA, LRRK2 and genes previously described (Park, Davis, & Sue, 
2018). Therefore, there is strong evidence supporting the importance of these genes in PD 
pathogenesis. 
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Specific Aims 
Specific aims of the following thesis are to:  
1. Provide a comprehensive literature review on past and current developments 
regarding the role of mitochondrial dysfunction in the etiology of PD. 
2. Examine published evidence regarding current treatments and therapies that target 
mitochondrial mechanisms toward improving Parkinson’s Disease 
pathophysiology. 
3. Discuss past and novel treatments and therapies that warrant further investigation. 
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PUBLISHED DATA 
 
Mitochondrial Dysfunction and Lewy Body Pathogenesis 
 In order to investigate the association between PD Lewy body pathology and 
mitochondrial dysfunction, a research study conducted by (Hsu et al., 2000) used a 
hypothalamic neuronal cell-line to investigate the effects of ASN accumulation on 
mitochondrial dysfunction and oxidative stress. They used the GT1-7 murine 
hypothalamic tumor cell line, and transfected the cells with plasmids that contained 
SNCA autosomal dominant gene mutations for overexpression of ASN. These cells were 
referred to as sense-transfected cells (ST cells). ASN overexpression in ST cells resulted 
in the formation of ASN-immunopositive inclusion-like structures and showed 
mitochondrial dysfunction and increased levels of free radicals. Dysfunctional 
mitochondria showed significant increases in size, vacuolization of cristae, and distorted 
morphology, as illustrated in Figure 3 below. 
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Figure 3. Ultrastructural analysis of mitochondrial alterations in transfected GT1-7 cells. A, B, and C 
show ST cells demonstrating normal morphology and appearance, and D, E, and F display ST cells 
demonstrating distorted morphology with abnormally enlarged mitochondria and vacuolization of 
mitochondrial cristae. Reprinted from (Hsu et al., 2000). 
 
 
Furthermore, cells transfected with high levels of ASN showed a 30% reduction 
in mitochondrial activity as compared to non-transfected control (Hsu et al., 2000), as 
shown in Figure 2 below. Mitochondrial activity was measured using a MTT assay.  
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Figure 2. MTT assay in transfected GT1-7 cells. α-Synuclein sense-transfected (ST) cells showed a 
significant 30% decrease in mitochondrial activity compared to nontransfected control (C). Treatment with 
the anti-oxidant vitamin E restored normal mitochondrial function in ST cells. Adapted from (Hsu et al., 
2000). 
 
Ultimately, the research study shows a marked decrease in mitochondrial function 
and abnormalities in mitochondrial structure and morphology in cells transfected with 
ASN, and provides a reliable in-vitro example supporting the contention that ASN is 
involved in regulating mitochondrial activity and that alterations in ASN expression may 
lead to mitochondrial dysfunction and elevation of free radical levels, which may 
eventually result in the neurodegeneration associated with Lewy Body pathology (Hsu et 
al., 2000). 
In order to examine in-vivo associations between mitochondrial dysfunction and 
PD pathology, research conducted by (Chinta et al., 2006) used transgenic mice that 
expressed the familial A53T mutant form of ASN protein in dopaminergic neurons. The 
A53T mutant form of ASN protein is known to be aggregate more than wild-type ASN.  
 
  
13
 
Figure 4. Quantitation of autophagic mitochondria in midbrain dopaminergic neurons of A53T high 
versus low-expressing α-syn-expressing transgenic mice at 12 months of age. A displays representative 
electron micrographs prepared from substantia nigra sections from A53T mutated synuclein high vs low-
expressing (HE vs LE) transgenic mice at 12 months of age. B displays a graph of autophagic mitochondria 
versus total mitochondria in midbrain dopaminergic neurons in LE vs HE transgenic mice. Adapted from 
(Chinta et al., 2006). 
 
 
Ultrastructural studies of dopaminergic neuronal mitochondria from HE versus 
LE A53T ASN mice demonstrated a significant increase in lysosome-mediated 
mitochondrial autophagy (mitochondria sequestered into double-membrane 
autophagosomes) within the HE mice, as shown in Figure 4 above.  
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Therefore, there is reliable evidence both in-vitro and in-vivo for the association 
between Lewy Body pathology and mitochondrial dysfunction and changes in 
mitochondrial morphology.  
 
Genetic Overlap Between Mitochondrial Dysfunction and PD 
There are genes that have been identified as being associated with PD as a 
causative factor or a risk factor. It is of interest to explore the role these genes play in 
mitochondrial activity, to determine any genetic overlap between PD pathophysiology 
and mitochondrial dysfunction that may provide evidence for an association between the 
two.  
Among gene mutations associated with PD, the G2019S mutation of the leucine 
rich repeat kinase 2 (LRRK2) enzyme is known to be the most common genetic cause of 
the disease, and occurs in both sporadic and familial PD patients. PD patients inherit the 
G2019S mutation in an autosomal-dominant pattern. LRRK2 is an enzyme in humans 
that is encoded by the PARK8 gene (Paisán-Ruı́z et al., 2004).  The enzyme is largely 
present in the cytoplasm but is also associated with the mitochondrial outer membrane. 
The G2019S mutation is caused by a glycine to serine substitution in the protein kinase 
domain encoded by exon 41 (Bouhouche et al., 2017). There is evidence for an 
association between G2019S mutated LRRK2 and dysfunctional mitochondrial activity. 
In a research study conducted by (Papkovskaia et al., 2012), fibroblasts derived from 
patients expressing the G2019S LRRK2 mutation were examined. Researchers used 
extracellular phosphorescent oxygen probes to assess mitochondrial function. They 
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discovered that the G2019S mutation was associated with mitochondrial uncoupling, 
which led to decreased mitochondrial membrane potential and increased oxygen 
utilization, as shown in Figure 5, which shows evidence of a significant increase in 
oxygen consumption in G2019S LRRK2 fibroblasts compared to control.  Mitochondrial 
uncoupling ultimately led to a decrease in cellular ATP levels associated with impaired 
cellular function. 
 
 
Figure 5. Mitochondrial function in G2019S LRRK2 patient fibroblasts. Mitochondrial function was 
assessed in fibroblast cell lines expressing MT G2019S LRRK2 (G2019S) and controls (control). Rates of 
cellular oxygen consumption in the presence of glucose were increased in the MT cells as determined by 
(A) an extracellular phosphorescent oxygen probe measured in relative fluorescence unit (RFU)/min/µg 
protein and (B) a Clark-type oxygen electrode measured in nmole O/min/µg protein. Reprinted from 
(Papkovskaia et al., 2012). 
 
 
Mutations in the parkin gene, known as PARK2, are the most common cause of 
autosomal recessive PD. The gene normally codes for the 465 amino acid ubiquitin ligase 
parkin that is capable of mediating ubiquitination through lysine 29, 48, and 63 of 
ubiquitin. The ubiquitin ligase parkin exists in an auto-inhibited state, and when 
activated, mediates its ubiquitination effects in the cytosol, mitochondria, synaptic 
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terminals, and the nucleus (Scarffe et al., 2014). In particular, parkin plays a key role in 
mitophagy and in removing reactive oxygen species (Olszewska & Lynch, 2015). 
Following cellular damage, mitochondrial membrane potential dissipates, causing PTEN-
induced kinase 1 (PINK1) to congregate in the outer mitochondrial membrane. Parkin is 
phosphorylated by PINK1, achieving its active form. Parkin then promotes ubiquitination 
of key mitochondrial proteins, signaling them for proteosomal degradation, and 
segregating defective mitochondria from functional ones (Scarffe et al., 2014). 
 
 
Figure 6. Model for PARKIN activation and recruitment onto damaged mitochondria. Following a 
loss in mitochondrial membrane potential, PINK1 accumulates on depolarized mitochondria. (1) When 
present on the outer mitochondrial membrane, PINK1 phosphorylates both S65 in the N-terminal of parkin 
and S65 within the ubiquitin moieties in ubiquitin conjugates that are attached to mitochondrial substrates 
on the outer mitochondrial membrane. (2) These phosphorylation events activate parkin and elicit its 
mitochondrial recruitment via direct interaction with the phospho-ubiquitin conjugates on the mitochondria. 
(3) Active parkin promotes the ubiquitination of multiple mitochondrial substrates. PINK1 phosphorylates 
these ubiquitin conjugates, which in turn acts as a feed-forward mechanism to further promote parkin 
activation and recruitment. (IMM) Inner mitochondrial membrane; (OMM) outer mitochondrial 
membrane.Reprinted from (Durcan & Fon, 2015). 
 
 
 
  
17
PINK1 gene mutations represent the second most common cause of autosomal recessive 
PD (Park, Davis, & Sue, 2018). PINK1 is a mitochondrial serine/threonine-
protein kinase encoded by the PARK6 gene (Unoki & Nakamura, 2001). PINK1, 
normally localized in the outer mitochondrial membrane, activates and recruits parkin to 
damaged and depolarized mitochondria, as shown in Figure 6 above, where parkin then 
facilitates ubiquitination of mitochondrial proteins, leading to proteosomal degradation 
and mitophagy (Narendra et al, 2012). Parkin and PINK1 are therefore interrelated in 
their mechanisms of action, as they normally work together to maintain mitochondrial 
homeostasis. 
 Loss of function of parkin and PINK1 have shown pathophysiology similar to 
PD. In a study conducted by (Pickrell et al., 2015), dopaminergic neurons were shown to 
degenerate in a PD pathogenic process after the loss of endogenous parkin in a mouse 
model of mitochondrial dysfunction. Researchers used mice homozygous for a 
proofreading deficiency in DNA polymerase γ (mutator mice). The mice display a 
progressive accumulation of mitochondrial DNA mutations, leading to impaired 
mitochondrial function (Kujoth et al., 2005). Mutator mice were crossed with parkin-
knockout mice to ultimately obtain four different groups: mutator mice, mutator-parkin-
knockout mice, parkin-knockout mice, and wild-type mice. Dopaminergic neurons were 
quantified from mice sacrificed at 48-52 weeks of age. Results indicated that endogenous 
parkin expression protected dopaminergic neurons from mitochondrial dysfunction, with 
loss of parkin resulting in worsening of mitochondrial function in dopaminergic neurons, 
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as quantified in Figure 7 by measurement of complex I, III, IV and citrate synthase 
mitochondrial activity. 
 
Figure 7. Mitochondrial Dysfunction Is Exacerbated after the Loss of Parkin. (A) Complex I 
enzymatic activity assays measuring striatal homogenates of 48- to 52-week-old mice. n = 4 to 5/group. (B) 
Complex III enzymatic activity assays measuring striatal homogenates of 48- to 52-week-old mice. n = 4 to 
5/group. (C) Complex IV enzymatic activity assays measuring striatal homogenates of 48- to 52-week-old 
mice. n = 4 to 5/group. (D) Citrate synthase activity assays measuring striatal homogenates of 48- to 52-
week-old mice. n = 4 to 5/group. Adapted from (Pickrell et al., 2015). 
 
In particular, the mutator-parkin-knockout mice exhibited phenotypes and 
pathology similar to PD that included dopaminergic neuron loss, depletion of dopamine 
in the striatum, and motor disturbances (Pickrell et al., 2015).  
Loss-of-function mutations in the PINK1 gene are the second most frequent cause 
of autosomal recessive PD, and a known cause of sporadic PD (Corti, Lesage, & Brice, 
2011). In a study conducted by (Pimenta de Castro et al., 2012), it was shown that 
mutations in human PINK1 protein result in higher levels of misfolded mitochondrial 
components and pathologies related to neurological proteinopathies like PD. Recently, 
PINK1 was identified as a modulator of the mitochondrial serine kinase HtrA2, 
phosphorylating it and activating its proteolytic activity, contributing to the increased 
resistance of cells to mitochondrial stress (Plun-Favreau et al., 2007). Researchers 
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examined the post-mortem brains of PD patients carrying PINK1 mutations that affect the 
phosphorylation status of HtrA2. They discovered an increased level of misfolded 
mitochondrial respiratory components in dopaminergic neurons, as shown in Figure 8. 
Researchers examined patients carrying the Y431H or C575R heterozygous PINK1 gene 
mutations, both of which lead to reduced levels of phosphorylated HtrA2. Researchers 
also examined patients that had idiopathic PD that had no known mutations in the PINK1 
gene. Results indicated that an enrichment of respiratory complex subunits in both 
PINK1 mutants. 
 
Figure 8. In vivo analysis of mitochondrial protein misfolding. Analysis of respiratory complex 
solubility in human brains. Human brain tissue (cortex) was analyzed by western blotting. Normal 
control brains (control); idiopathic Parkinson's disease brains (IPD); and PD brains carrying 
mutant PINK1 were analyzed. Protein fractions were prepared under gentle lysis conditions and 
compared with SDS-extracted proteins. Adapted from (Pimenta de Castro et al., 2012). 
 
The above results ultimately provide overwhelming evidence for the association 
Parkin and PINK1 gene mutations in contributing to PD pathology through disruption of 
healthy mitochondrial mechanisms.  
Sporadic causes of PD are multifactorial, with familial genes associated with PD 
potentially playing a role in the onset and progression of sporadic cases. Notably, it has 
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been shown that mutations in the gene for β-glucocerebrosidase, GBA, play a role in the 
onset and progression of PD symptoms, and there is strong evidence for an association 
between GBA mutations and mitochondrial dysfunction that leads to the pathophysiology 
of PD. 
β-glucocerebrosidase is an enzyme with glucosylceramidase activity and breaks 
down glycolipids (Neumann et al., 2009). The enzyme is needed to hydrolytically cleave 
glucocerebroside, which is an intermediate of glycolipid metabolism that is present in cell 
membranes. The GBA gene is the gene that is deficient in the lysosomal storage disease, 
Gaucher’s Disease, which is caused by the accumulation of glucocerebroside in tissue 
(Sidransky, 2012). A study was done by (Gan-Or et al., 2008) on an Israeli Ashkenazi 
cohort of 420 Parkinson’s Disease patients, 333 elderly controls, and 3805 young 
controls.  The study revealed that patients with PD had a GBA gene carrier frequency of 
17.9% as compared to only 4.2% in the elderly controls, and 6.35% in young controls. 
Their study showed that the proportion of severe GBA mutation carriers among 
Parkinson’s Disease patients was 29% as compared to 7% among young controls. In 
another study by (Clark et al., 2007) involving a sample of 278 PD cases and 179 
controls, it was shown that 13.7% of PD cases carried GBA mutations, as opposed to 
4.5% in controls. Furthermore, they showed that the frequency of GBA mutations was 
22.2% in 90 cases with an age at onset of PD of less than 50 years old, as compared to 
9.7% in patients with an age at onset of over 50 years old. Therefore, data reveals that 
there is a significant genetic correlation between GBA mutations and both the 
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development of Parkinson’s Disease pathology, along with the age at which the disease 
presents itself. 
 Research was done on human induced pluripotent stem cell iPS neurons in order 
to examine the pathological effects of a functional loss of glucocerebrosidase in-vitro 
(Mazzulli et al., 2011).  Researchers created a GBA loss-of-function model by using 
shRNA-mediated knock-out by lentiviral infection. As a control, researchers used non-
transduced control scrambled (scrb) neurons. GBA knock-out neurons showed a 50% 
reduction in GBA protein levels as compared to non-transduced neurons. When 
examining the GBA knock-out neurons compared to control neurons, it was observed that 
GBA knock-out neurons displayed a 40% decrease in the rate of proteolysis. More 
specifically, GBA knock-out neurons displayed a decreased ability to dispose of 
endogenous ASN, showing a 1.8 fold increase in accumulated ASN compared to control, 
as displayed in figure 9. 
 
 
Figure 9. Analysis of α-syn levels after GCase knock-out. GC shRNA = GCase knock-out neurons. scrb 
shRNA = control neurons. Adapted from (Mazzulli et al., 2011) 
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Researchers ultimately discovered that a functional loss of glucocerebrosidase 
leads to accumulation of ASN, and ultimately, neurotoxicity characteristic of 
synucleiopathies (Mazzulli et al., 2011). Therefore, mutations in the GBA represent a 
genetic risk factor for developing Parkinson’s Disease.  
 Due to the relationship between the GBA mutation and Parkinson’s 
Disease/Gaucher’s Disease, and the relationship between mitochondrial dysfunction and 
Parkinson’s Disease, it is of interest to explore the relationship between the GBA 
mutation and mitochondrial biogenesis, to ascertain whether there is an association.  
Research shows that a deficiency in glucocerebrosidase (GCase) diminishes 
mitochondrial function, with mitochondria-dense neurons displaying the consequences. 
Inhibition of GCase by CBE in SH-SY5Y neuroblastoma cells resulted in a significant 
decrease in mitochondrial membrane potential after 10 days, and decreased progressively 
up to 30 days of CBE treatment. (Cleeter, et al., 2013). Mitochondrial dysfunction was 
also shown to occur in Gaucher’s Disease fibroblasts and Gaucher’s Disease mouse 
models. According to research done by (de la Mata et al., 2015), levels of the respiratory 
chain electron carrier coenzyme Q10 (CoQ10) were reduced by 24% in these GD 
fibroblasts. ATP levels were decreased by 30% in these fibroblasts and an increased 
production of the free radical superoxide by mitochondria was also detected. 
Therefore, there is evidence for an association between the GBA mutation and 
mitochondrial function. While it is important to note that mitochondrial dysfunction in 
and of itself does not necessarily lead to PD pathology, as many diseases unrelated to PD 
are the result of mitochondrial deficits, when coupled with ASN accumulation and the 
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importance of mitochondria for the high-energy needs of neurons, GBA mutations could 
potentially enhance the pathogenesis of PD through mitochondrial dysfunction.  
 
Antioxidant Therapies for Mitochondrial-Associated PD  
Evidence for an association between mitochondrial dysfunction and dopaminergic 
neurodegeneration in PD suggests that oxidative stress is a major contributing factor (Jin 
et al., 2014). Antioxidant compounds may provide a route for repairing mitochondrial 
dysfunction in PD, and therefore are promising as potential therapies for treating PD. A 
few major antioxidant therapies will be explored.  
Many natural compounds are known to have anti-oxidant properties. One of the 
most commonly occurring natural sources of antioxidants are green tea polyphenols. Of 
particular interest is the active component of green tea polyphenols, the catechin 
epigallocatechin gallate (EGCG), also known as epigallocatechin-3-gallate, which has 
gained attention for preventing neurodegenerative diseases due to its antioxidant 
therapeutic potential (Singh, Mandal, & Khan, 2016). A research study conducted by 
(Levites, Weinreb, Maor, Youdim, & Mandel 2001) tested EGCG’s neuroprotective 
properties on a N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mice model of 
Parkinson's disease. MPTP neurotoxin caused dopamine neuron loss in the substantia 
nigra concomitant with a depletion in striatal dopamine and tyrosine hydroxylase protein 
levels, mirroring the pathology of PD. Mice were pretreated with 2 and 10 mg/kg of 
EGCG orally for 10 days to achieve a chronic consumption of the polyphenol and then 
MPTP was administered in combination with EGCG for another 4 days. EGCG was 
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ultimately shown to reduce the dopamine neuron loss, showing a simultaneous increase 
in the striatal antioxidant enzymes superoxide dismutase and catalase.  
 
Figure 10. Effect of EGCG on striatal dopamine content in MPTP‐treated mice. Mice received EGCG 
(2 and 10 mg/kg, orally) for 10 days and the following four days the animals received a combination of 
EGCG and MPTP (24 mg/kg/day). Controls received saline or EGCG only. Striatal DA was measured by 
HPLC. (n=6 mice). One‐way ANOVA conducted versus MPTP. Reprinted from (Levites, Weinreb, Maor, 
Youdim, & Mandel 2001). 
 
 
Another study conducted by Ding et al. (2018) examined the effects of an 
antioxidant treatment on mitochondrial dysfunction caused by ASN accumulation. The 
association between ASN accumulation and mitochondrial dysfunction occurs through 
interaction with mitochondrial complex I (Ding et al., 2018), and overexpression of ASN 
has been implicated in the elevation of mitochondrial reactive oxygen species and 
functional defects in mitochondria. Researchers treated SH-SY5Y human neuroblastoma 
cells with rotenone to mimic PD pathology. Rotenone is a potent mitochondrial complex 
I inhibitor and causes the loss of ATP and the build-up of ASN levels and oxidative stress 
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(Ding et al., 2018). Rotenone-induced PD in in-vitro models are used to screen for anti-
PD drugs. After exposure of 5 nM of rotenone for 4 weeks, neuroblastoma cells were 
treated with various concentrations of the antioxidant triterpenoid asiatic acid (AA) after 
24 hours. By recording changes in mitochondrial membrane potential using the 
fluorescent dye JC-1, researchers revealed that treatment of AA served to weaken the 
decline in mitochondrial membrane potential induced by alpha-synuclein. AA treatment 
also served to maintain membrane integrity, ATP production, and prevent the movement 
of ASN into mitochondria.  
 
 
 
 
Figure 11. AA protects against mitochondrial dysfunction induced by PD-like injury. (A,B) SH-SY5Y 
cells were treated with 5 nM rotenone exposure for 4 weeks and then various concentrations of AA after 24 
h. Intracellular red and green fluorescence of JC-1 was determined under an inverted fluorescence 
microscope (A) and on a spectrofluorometer (B). Adapted from Ding et al., 2018. 
 
 
Figure 10 demonstrates the protective effects of the antioxidant AA in preventing 
mitochondrial structural damage induced by ASN. With application of AA, cellular death 
was reduced due to an increase in antioxidant activity by AA in mitochondria. The 
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treatment with AA reveals that improvement of PD pathology is associated, at least in 
part, with improved mitochondrial function, and that antioxidant activity potentially plays 
a role in improvement of PD pathology. 
  
β2-adrenoreceptor Agonist Treatment for Mitochondrial-Associated PD 
In the search for potential treatments aimed at reducing PD pathology through 
targeting mitochondrial mechanisms, β2-adrenoreceptor compounds have proven to be 
promising targets. A research study showed in a small-molecule screen, initially 
consisting of over 1100 drugs examined for their efficacy in reducing ASN production, 
that β2-adrenoreceptor (β2AR) agonists modulated epigenetic markers at the SNCA gene 
location, effectively reducing the expression of the SNCA gene (Mittal et al., 2017).  
After narrowing in on a group of β2AR agonists, they studied the effects of the 
compounds in mice, finding that they significantly reduced ASN levels. Researchers also 
conducted a pharmaceutical history of over four million Norwegians over an 11-year 
period (Mittal et al., 2017). The study showed that patients who were taking the β2AR 
agonist salbutamol, which is used to treat asthma, were significantly less likely to 
develop Parkinson’s Disease, with risk for developing the disease reduced by 34%. In 
contrast, those individuals taking propranolol, a hypertension drug and β2AR antagonist, 
were at a greater risk of developing Parkinson’s Disease. β2AR compounds were shown 
in their studies to regulate the expression of SNCA, with some of these compounds being 
able to reduce SNCA expression.  
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While inducing mitochondrial biogenesis stimulates cell repair and regeneration, 
few chemical compounds are known to induce mitochondrial biogenesis (Peterson et al., 
2013). However, mitochondrial biogenesis can be stimulated by the same β2-
adrenoreceptor compounds that have been implicated in the reduction of Parkinson’s 
Disease pathology (Peterson et al., 2013). Of particular interest is the β2 adrenoreceptor 
agonist formoterol, which has already been used as a bronchodilator in the management 
of asthma and chronic obstructive pulmonary disease. A research study revealed that 
mice treated with formoterol for 24 or 72 hours exhibited increases in mitochondrial 
DNA copy number in the kidney and heart, and offers compelling evidence for 
therapeutic use of formoterol for inducing mitochondrial biogenesis (Wills et al., 2012). 
β2 adrenoreceptor therefore provide a promising potential target for future PD treatments. 
By continuing to examine the effect of these β2 adrenoreceptor compounds on brain 
tissue affected by PD pathology, a greater understanding of the correlation between 
mitochondrial biogenesis and PD can be attained.  
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DISCUSSION AND CONCLUSION 
 
There is overwhelming evidence supporting an association between mitochondrial 
dysfunction and Parkinson’s Disease pathophysiology, stemming from interactions 
between the alpha-synuclein protein and the mitochondrial membrane. It has also been 
shown that PD-associated gene mutants have a role in maintaining mitochondrial 
function. Genes that play a role in PD onset and progression were shown to have a role in 
maintaining mitochondrial homeostasis and function, and evidence shows overlap 
between the two roles, indicating that mitochondrial dysfunction contributes to 
Parkinsonism. 
There is promising evidence for therapies and treatments that could target 
parkinsonism through mitochondrial pathways. There are promising antioxidant therapies 
for addressing parkinsonism through improvement of mitochondrial dysfunction caused 
by oxidative stress. Furthermore, beyond antioxidant therapies, β2-adrenoreceptor 
compounds may provide potential therapeutic drugs for treating Parkinsonism through 
inducing mitochondrial biogenesis and preventing neurodegernation.  
Published data referenced in this review provides evidence to support further 
research into mitochondrial dysfunction and parkinsonism, with a focus on discovering 
new genetic and biochemical associations between the two, along with pursuing the 
development of treatments and therapies that combat parkinsonism through addressing 
mitochondrial deficits. 
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